ADMA · Adma Biologics, Inc. · Webcasts, Transcripts & Audio
$10.20
+0.48 (+4.94%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$2.20B
Shares
223.98M
Volume · Oct 5
3.51M
Avg daily vol (3M)
2.61M
Adma Biologics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Adma Biologics, Inc. (ADMA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲98.7%
$41.09M
−$14.90M
'22 Q3
22-11-09
▲89.4%
$49.98M
−$12.23M
'22 Q4
23-03-23
▲95.6%
$56.91M
−$6.79M
'23 Q1
23-05-10
▲77.3%
$60.12M
−$6.37M
'23 Q2
23-08-09
▲63.7%
$67.28M
$2.56M
'23 Q3
23-11-08
▲47.9%
$73.90M
−$17.64M
'23 Q4
24-01-08
▲43.9%
$81.88M
$17.81M
'24 Q1
24-05-09
▲78.3%
$107.19M
$32.06M
'24 Q2
24-08-08
▲78.1%
$119.84M
$35.91M
'24 Q3
24-11-07
▲59.1%
$117.55M
$111.90M
'24 Q4
25-03-03
▲40.2%
$114.80M
$26.90M
'25 Q1
25-05-07
▲13.8%
$121.98M
$34.22M
'25 Q2
25-08-06
▲12%
$134.22M
$36.43M
'25 Q3
25-11-05
▲18.4%
$139.16M
$49.38M
'25 Q4
26-02-25
▼0.3%
$114.49M
$45.33M
'26 Q1
26-05-06
LATEST
▲2%
$124.39M
$37.82M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Adma Biologics, Inc. (ADMA) Q2 2026 Earnings Call
Revenue
$124.39M
▲ 2% YoY Diluted EPS
$0.16
▲ 14.3% YoY Gross margin
69.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Adma Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
Positive tone
Ascentive demand growth
Pediatric label expansion
Vivigam competitive pressure
Revenue
$114.49M
▼ 0.3% YoY Diluted EPS
$0.19
▲ 72.7% YoY Gross margin
70.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Adma Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
Confident tone
Financial results and profitability
Ascentive product growth and demand
Yield-enhanced manufacturing
Revenue
$139.16M*
▲ 18.4% YoY Gross margin
63.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Adma Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript
Confident tone
ASCENIV growth and prescriber adoption
Financial performance and profitability
Capital deployment and guidance
Revenue
$134.22M
▲ 12% YoY Diluted EPS
$0.15
▲ 0% YoY Gross margin
56.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Adma Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript
Confident tone
Revenue Growth & Financial Performance
Yield Enhancement / Manufacturing Efficiency
Facility Expansion & Capacity Planning
Revenue
$121.98M
▲ 13.8% YoY Diluted EPS
$0.14
▲ 7.7% YoY Gross margin
55.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Adma Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
Confident tone
Revenue Growth and Guidance
ASCENIV Franchise and Durability
Yield Enhancement Production Process
Revenue
$114.80M
▲ 40.2% YoY Diluted EPS
$0.11
▲ 37.5% YoY Gross margin
53.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Adma Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript
Confident tone
Revenue and earnings momentum
ASCENIV product growth and market penetration
Enhanced yield production process (regulatory)
Revenue
$117.55M*
▲ 59.1% YoY Gross margin
53.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Adma Biologics, Inc. (ADMA) Q3 2024 Earnings Call Transcript
Confident tone
ASCENIV Commercial Momentum
Yield Enhancement Initiative
Revenue and Earnings Growth
Revenue
$119.84M
▲ 78.1% YoY Diluted EPS
$0.15
▲ 1400% YoY Gross margin
49.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Adma Biologics, Inc. (ADMA) Q2 2024 Earnings Call Transcript
Confident tone
ASCENIV demand and penetration
Raised financial guidance
Revenue growth and milestone
Revenue
$107.19M
▲ 78.3% YoY Diluted EPS
$0.13
Gross margin
53.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Adma Biologics, Inc. (ADMA) Q1 2024 Earnings Call Transcript
Confident tone
Asceniv commercial momentum
Post-2025 outlook uncertainty
Revenue growth and outperformance
Revenue
$81.88M
▲ 43.9% YoY Diluted EPS
$0.08
Gross margin
47.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Adma Biologics, Inc. (ADMA) Q4 2023 Earnings Call Transcript
Confident tone
Forward Guidance / Outlook
ASCENIV Product Performance
Revenue and Earnings Growth
Revenue
$73.90M*
▲ 47.9% YoY Gross margin
42.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Adma Biologics, Inc. (ADMA) Q3 2023 Earnings Call Transcript
Revenue
$67.28M
▲ 63.7% YoY Diluted EPS
$0.01
Gross margin
36.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Adma Biologics, Inc. (ADMA) Q2 2023 Earnings Call Transcript
Revenue
$60.12M
▲ 77.3% YoY Diluted EPS
$-0.03
Gross margin
27.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Adma Biologics, Inc. (ADMA) Q1 2023 Earnings Call Transcript
Revenue
$56.91M
▲ 95.6% YoY Diluted EPS
$-0.03
Gross margin
29.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Adma Biologics, Inc. (ADMA) Q4 2022 Earnings Call Transcript
Revenue
$49.98M*
▲ 89.4% YoY Gross margin
28.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Adma Biologics, Inc. (ADMA) Q3 2022 Earnings Call Transcript
Revenue
$41.09M
▲ 98.7% YoY Diluted EPS
$-0.08
Gross margin
23.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Adma Biologics, Inc. (ADMA) Q2 2022 Earnings Call Transcript
Revenue
$33.91M
▲ 90.2% YoY Diluted EPS
$-0.07
Gross margin
22.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Adma Biologics, Inc. (ADMA) Q1 2022 Earnings Call Transcript
Revenue
$29.10M
▲ 81.3% YoY Diluted EPS
$-0.13
Gross margin
12.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-19
Adma Biologics, Inc. (ADMA) Q4 2021 Earnings Call Transcript
Revenue
$26.38M*
▲ 89% YoY Gross margin
13.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-20
Adma Biologics, Inc. (ADMA) Q3 2021 Earnings Call Transcript
Revenue
$20.68M
▲ 101.2% YoY Diluted EPS
$-0.13
Gross margin
1.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Adma Biologics, Inc. (ADMA) Q2 2021 Earnings Call Transcript
Revenue
$17.83M
▲ 129% YoY Diluted EPS
$-0.15
Gross margin
-5.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Adma Biologics, Inc. (ADMA) Q1 2021 Earnings Call Transcript
Revenue
$16.05M
▲ 57.3% YoY Diluted EPS
$-0.16
Gross margin
-10.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Adma Biologics, Inc. (ADMA) Q4 2020 Earnings Call Transcript
Revenue
$13.96M*
▲ 15.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Adma Biologics, Inc. (ADMA) Q3 2020 Earnings Call Transcript
Revenue
$10.28M
▲ 42.3% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Adma Biologics, Inc. (ADMA) Q2 2020 Earnings Call Transcript
Revenue
$7.79M
▲ 18.7% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Adma Biologics, Inc. (ADMA) Q1 2020 Earnings Call Transcript
Revenue
$10.20M
▲ 189.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-13
Adma Biologics, Inc. (ADMA) Q4 2019 Earnings Call
Revenue
$12.04M*
▲ 196.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 webcasts
Key facts
CIK
1368514
CUSIP
000899104
13F (30d)
10 filings
7 filers
Visit website
Investor relations